Session: MON 596-630-Pediatric Endocrinology
Poster Board MON-611
Study Design: Double blind, randomized trial in 12-18 year old obese adolescents (BMI > 95th percentile). Participants were prospectively randomized to receive either 2000 IU/day (n=23) or 400 IU (n=23) vitamin D3, orally for 12 weeks. Total [25(OH)D] and risk factors of CMD such as fasting plasma glucose, insulin, total cholesterol, high density cholesterol, triglycerides, high sensitivity C-reactive protein (hsCRP), interleukin- 6 (IL-6), total (T) adiponectin, high molecular weight (HMW) adiponectin and retinol binding protein 4 (RBP4) were measured at baseline and at the end of the 12 week supplementation.
Results: Mean 25(OH)D levels at baseline were similar in both groups. While the [25(OH)D] concentration increased ( median 5 ng/ml; range -8 to 15.1, p=0.039) in the 2000 IU/day group, the change in the 400 IU/day group was negligible ( range -8 to 9, p=0.4). Irrespective of the dose of vitamin D3, the risk factors of CMD did not show any appreciable changes (all p>0.05) in both groups.
Conclusions: Although the higher dose of 2000 IU/day vs. 400 IU/day produced a modest increase in serum 25(OH)D, neither resulted in beneficial changes in obesity-related risk factors of CMD. These results are intriguing and suggest the potential need for higher doses of vitamin D in obese adolescents, particularly in those with vitamin D deficiency. On the other hand it is likely that the modulation of risk factors of obesity-related CMD is not solely dependent on vitamin D status in children. Considering obesity-related vitamin D insufficiency and the increased prevalence of CMD, it is crucial that future studies focus on higher doses of vitamin D and/or longer duration of supplementation along with more sophisticated measures of insulin resistance and other markers of CMD to understand the role of vitamin D in modulating alterations in risk factors of CMD in obese children and adolescents.
Nothing to Disclose: AJ, PPB, AV, PF, AW, JL, PG, SK
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters